US Patent

US8747897 — Osmotic drug delivery system

Method of Use · Assigned to Supernus Pharmaceuticals Inc · Expires 2031-08-11 · 5y remaining

Vulnerability score 73/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects an osmotic drug delivery system for highly water-soluble drugs that exhibit an erratic or incomplete release profile.

USPTO Abstract

An oral osmotic pharmaceutical delivery system comprises a highly water-soluble drug exhibiting an erratic or an incomplete release profile when formulated in a elementary osmotic pump delivery system and at least one release enhancing agent.

Drugs covered by this patent

treprostinil-diolamine (TREPROSTINIL DIOLAMINE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2725`	—	treprostinil-diolamine
`U-2724`	—	treprostinil-diolamine
`U-2725`	—	treprostinil-diolamine
`U-2725`	—	treprostinil-diolamine
`U-2725`	—	treprostinil-diolamine

Patent Metadata

Patent number: US8747897
Jurisdiction: US
Classification: Method of Use
Expires: 2031-08-11
Drug substance claim: No
Drug product claim: Yes
Assignee: Supernus Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.